Aelis Farma SA (EPA:AELIS)

France · Delayed Price · Currency is EUR

0.7000

-0.0180 (-2.51%)

Oct 23, 2026, 9:06 AM CEST

Market Cap	9.52M -37.8%
Revenue (ttm)	2.19M +23.1%
Net Income	-4.74M
EPS	-0.35
Shares Out	13.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,851
Open	0.7000
Previous Close	0.7180
Day's Range	0.7000 - 0.7000
52-Week Range	0.7000 - 2.3000
Beta	0.64
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 16, 2026

About Aelis Farma

Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company owns a pipeline of pharmacological inhibitors, including AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; AEF0217, a drug candidate, which is in phase 1/2 clinical trials to treat cognitive deficits observed in down syndrome; and CB1-SSi, a new molecular entities to treat oth... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2013

Employees 14

Stock Exchange Euronext Paris

Ticker Symbol AELIS

Full Company Profile

Financial Performance

In 2025, Aelis Farma's revenue was 2.08 million, a decrease of -62.53% compared to the previous year's 5.56 million. Losses were -6.43 million, -13.71% less than in 2024.

Financial Statements